Randomized, Open-Label Phase 3 Study Evaluating Immunogenicity, Safety, and Reactogenicity of RSVPreF3 OA Coadministered with FLU-QIV-HD in Adults Aged ≥ 65
Sign Up to like & getrecommendations! Published in 2024 at "Infectious Diseases and Therapy"
DOI: 10.1007/s40121-024-00985-4
Abstract: Respiratory syncytial virus (RSV) and influenza pose major disease burdens in older adults due to an aging immune system and comorbidities; seasonal overlap exists between these infections. In 2023, the RSV prefusion protein F3 older… read more here.
Keywords: adults aged; flu qiv; aged years; vaccine ... See more keywords